Skip to main content
Erschienen in: Current Osteoporosis Reports 1/2010

01.03.2010

Orthopedic Uses of Teriparatide

verfasst von: Susan V. Bukata, J. Edward Puzas

Erschienen in: Current Osteoporosis Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.
Literatur
1.
Zurück zum Zitat Burge RT, Dawson-Hughes B, Solomon D, et al.: Incidence and economic burden of osteoporotic fractures in the United States, 2005–2025. J Bone Min Res 2007, 22:465–475.CrossRef Burge RT, Dawson-Hughes B, Solomon D, et al.: Incidence and economic burden of osteoporotic fractures in the United States, 2005–2025. J Bone Min Res 2007, 22:465–475.CrossRef
2.
Zurück zum Zitat Kent GN, Loveridge N, Reeve J, et al.: Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin Sci (Lond) 1985, 68:171–177. Kent GN, Loveridge N, Reeve J, et al.: Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin Sci (Lond) 1985, 68:171–177.
3.
Zurück zum Zitat Hock JM, Gera I: Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992, 7:65–72.CrossRefPubMed Hock JM, Gera I: Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992, 7:65–72.CrossRefPubMed
4.
Zurück zum Zitat Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.CrossRefPubMed Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.CrossRefPubMed
5.
Zurück zum Zitat Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA: Growth factor regulation of fracture repair. J Bone Miner Res 1999, 14:1805–1815.CrossRefPubMed Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA: Growth factor regulation of fracture repair. J Bone Miner Res 1999, 14:1805–1815.CrossRefPubMed
6.
Zurück zum Zitat Simmons DJ: Fracture healing perspectives. Clin Orthop Relat Res 1985, 200:100–113.PubMed Simmons DJ: Fracture healing perspectives. Clin Orthop Relat Res 1985, 200:100–113.PubMed
7.
Zurück zum Zitat Kronenberg HM, Chung U: The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate. Novartis Found Symp 2001, 232:144–152.CrossRefPubMed Kronenberg HM, Chung U: The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate. Novartis Found Symp 2001, 232:144–152.CrossRefPubMed
8.
Zurück zum Zitat Andreassen TT, Ejersted C, Oxlund H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960–968.CrossRefPubMed Andreassen TT, Ejersted C, Oxlund H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960–968.CrossRefPubMed
9.
Zurück zum Zitat Andreassen TT, Willick GE, Morley P, Whitfield JF: Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004, 74:351–356.CrossRefPubMed Andreassen TT, Willick GE, Morley P, Whitfield JF: Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004, 74:351–356.CrossRefPubMed
10.
Zurück zum Zitat Alkhiary YM, Gerstenfeld LC, Krall E, et al.: Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005, 87:731–741.CrossRefPubMed Alkhiary YM, Gerstenfeld LC, Krall E, et al.: Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005, 87:731–741.CrossRefPubMed
11.
Zurück zum Zitat Manabe T, Mori S, Mashiba T, et al.: Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40:1475–1482.CrossRefPubMed Manabe T, Mori S, Mashiba T, et al.: Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40:1475–1482.CrossRefPubMed
12.
Zurück zum Zitat Friedl G, Turner RT, Evans GL, Dobnig H: Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007, 25:1454–1464.CrossRefPubMed Friedl G, Turner RT, Evans GL, Dobnig H: Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007, 25:1454–1464.CrossRefPubMed
13.
Zurück zum Zitat Rickard DJ, Wang FL, Rodriques-Rojas AM, et al.: Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39:1361–1372.CrossRefPubMed Rickard DJ, Wang FL, Rodriques-Rojas AM, et al.: Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39:1361–1372.CrossRefPubMed
14.
Zurück zum Zitat Nakazawa T, Makajima A, Shiomi K, et al.: Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37:711–719.CrossRefPubMed Nakazawa T, Makajima A, Shiomi K, et al.: Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37:711–719.CrossRefPubMed
15.
Zurück zum Zitat Kakar S, Einhorn TA, Vora S, et al.: Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903–1912.CrossRefPubMed Kakar S, Einhorn TA, Vora S, et al.: Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903–1912.CrossRefPubMed
16.
Zurück zum Zitat O’Loughlin PF, Cunningham ME, Bukata SV, et al.: Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 2009, 34:121–130.CrossRefPubMed O’Loughlin PF, Cunningham ME, Bukata SV, et al.: Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 2009, 34:121–130.CrossRefPubMed
17.
Zurück zum Zitat •• Aspenberg P, Genant HK, Johansson T, et al.: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2009 Jul 13 [Epub ahead of print]. This is the first placebo-controlled, double-blinded, randomized clinical trial investigating the use of teriparatide in humans to accelerate fracture healing. Although this study missed its primary end point with a dose greater than that which is used for osteoporosis, the trend for the dose currently used for osteoporosis suggests an effect. It is a fundamental study that all subsequent trials investigating biologic adjuvants for fracture healing will need to use as a comparator. •• Aspenberg P, Genant HK, Johansson T, et al.: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2009 Jul 13 [Epub ahead of print]. This is the first placebo-controlled, double-blinded, randomized clinical trial investigating the use of teriparatide in humans to accelerate fracture healing. Although this study missed its primary end point with a dose greater than that which is used for osteoporosis, the trend for the dose currently used for osteoporosis suggests an effect. It is a fundamental study that all subsequent trials investigating biologic adjuvants for fracture healing will need to use as a comparator.
18.
Zurück zum Zitat Resmini G, Iolascon G: 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007, 19(4 Suppl):30–31.PubMed Resmini G, Iolascon G: 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007, 19(4 Suppl):30–31.PubMed
19.
Zurück zum Zitat Bukata SV, Kaback L, Reynolds D, et al.: 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas, NV; February 25, 2009. Bukata SV, Kaback L, Reynolds D, et al.: 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas, NV; February 25, 2009.
21.
Zurück zum Zitat Desai A, Alavi A, Dalinka M, et al.: Role of bone scintigraphy in the evaluation and treatment on nonunited fractures: concise communication. J Nucl Med 1980, 21:931–934.PubMed Desai A, Alavi A, Dalinka M, et al.: Role of bone scintigraphy in the evaluation and treatment on nonunited fractures: concise communication. J Nucl Med 1980, 21:931–934.PubMed
22.
Zurück zum Zitat •• Chang JK, Chang LH, Hung SH, et al.: Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009, 60:3049–3060. This is the first animal study published looking at the potential role that teriparatide may play in treating early arthritis. •• Chang JK, Chang LH, Hung SH, et al.: Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009, 60:3049–3060. This is the first animal study published looking at the potential role that teriparatide may play in treating early arthritis.
25.
Zurück zum Zitat Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273–280.CrossRefPubMed Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273–280.CrossRefPubMed
Metadaten
Titel
Orthopedic Uses of Teriparatide
verfasst von
Susan V. Bukata
J. Edward Puzas
Publikationsdatum
01.03.2010
Verlag
Current Science Inc.
Erschienen in
Current Osteoporosis Reports / Ausgabe 1/2010
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-010-0006-3

Weitere Artikel der Ausgabe 1/2010

Current Osteoporosis Reports 1/2010 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.